Vilon

Vilon was synthesized by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Gerontology in the late 1990s as a minimal active thymus-mimetic dipeptide. What it is: It is a synthetic dipeptide (Lys-Glu) categorized under the Tissue Repair/Immune category. Proposed Mechanisms & Research Findings: It regulates gene expression in immune cells, stimulating chromatin reactivation, improving immune cell activity, and accelerating wound healing. Regulatory & Safety Status: It is not FDA approved. It is restricted to laboratory research. Unverified gray-market sourcing lacks safety control. Athletic & Anti-Doping Status: It is not prohibited by WADA, as it acts as a simple dipeptide immunomodulator.